APHEXDA

GrowthPeptide

motixafortide

NDASUBCUTANEOUSPOWDER

Approved

Sep 2023

Lifecycle

Growth

Competitive Pressure

0/100

Clinical Trials

Mechanism of Action

C-X-C Motif Chemokine Receptor 4 (CXCR4) and blocks the binding of its cognate ligand, stromal-derived factor-1α (SDF-1α)/C-X-C Motif Chemokine Ligand 12 (CXCL12). SDF-1α and CXCR4 play a role in the trafficking and homing of human hematopoietic stem cells to the marrow compartment. Once in the…

Indications (3)

combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection subsequent autologous transplantation in patients with multiple myeloma myeloma

Clinical Trials (3)

NCT06547112Phase 1Completed

A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization

Started Oct 2024

NCT05618301Phase 1Completed

Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

Started Jul 2023

10 enrolled

Sickle Cell Disease

NCT05293171Phase 1Completed

Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects

Started Jun 2021